Barrow, Hanley, Mewhinney & Strauss
AMRX icon

Barrow, Hanley, Mewhinney & Strauss’s Amneal Pharmaceuticals AMRX Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,576
Closed -$9.55K – 302
2024
Q1 		$9.55K Hold
1,576
– – ﹤0.01% 209
2023
Q4 		$9.57K Sell
1,576
-263
-14% -$1.17K ﹤0.01% 196
2023
Q3 		$7.76K Sell
1,839
-156
-8% -$582 ﹤0.01% 204
2023
Q2 		$6.18K Sell
1,995
-297
-13% -$633 ﹤0.01% 211
2023
Q1 		$3.19K Hold
2,292
– – ﹤0.01% 243
2022
Q4 		$4.56K Buy
2,292
+1,058
+86% +$2.37K ﹤0.01% 223
2022
Q3 		$2K Hold
1,234
– – ﹤0.01% 248
2022
Q2 		$4K Hold
1,234
– – ﹤0.01% 225
2022
Q1 		$5K Sell
1,234
-12,463
-91% -$55.2K ﹤0.01% 232
2021
Q4 		$66K Hold
13,697
– – ﹤0.01% 230
2021
Q3 		$73K Hold
13,697
– – ﹤0.01% 228
2021
Q2 		$70K Sell
13,697
-6,856
-33% -$39K ﹤0.01% 239
2021
Q1 		$138K Buy
20,553
+1,318
+7% +$7.3K ﹤0.01% 210
2020
Q4 		$88K Sell
19,235
-2,549
-12% -$11.3K ﹤0.01% 234
2020
Q3 		$84K Buy
+21,784
New +$93.2K ﹤0.01% 273
2020
Q2 		– Sell
-111,896
Closed -$390K – 317
2020
Q1 		$390K Buy
+111,896
New +$474K ﹤0.01% 236

Other funds holding AMRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's AMRX Position: Q2 2024 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Amneal Pharmaceuticals (AMRX) in Q2 2024, closing a stake of 1,576 shares — an estimated $9.55K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in AMRX in Q1 2020 and held it in 16 quarters. The position peaked at $390K in Q1 2020. 181 funds tracked by Wall St. Rank hold AMRX as of Q2 2024.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Amneal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 1,576 Amneal Pharmaceuticals shares in Q2 2024, an estimated $9.55K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Amneal Pharmaceuticals in Q1 2020 and held it in 16 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Amneal Pharmaceuticals position peaked at $390K in Q1 2020.
  • 181 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2024.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2024, filed 13 Aug 2024.